Skip to content
Science
Our Science
Autoimmunity
P140
Type M & Diagnostic
Type 1 Diabetes
Kapiglucagon
Anti-infectives
BioAMB
BioCIN
Pipeline
Company
Mission
About Us
Our Team
ImmuPharma Biotech
Investors
Investors
AIM Rule 26 Information
Regulatory News
Corporate Governance
Board of Directors
Annual Reports
Advisers
Email Alert
Updates
Announcements
Interviews
In the Media
Contact
Lanstead Capital TR1
Jan 4, 2021
Standard form for notification of major holdings
To download
click here
←
Previous:
ImmuPharma to present at Biotech Showcase™ Digital 2021
Next:
Appointment of Company Secretary
→
